Károly Palatka - Concepedia

Author

Károly Palatka

Also Known As

, Denis Franchimont, Gonçalo Alexandrino, Hungarian IBD Study Group, K Palatka, K. Palatka, Karoly K. Palatka, Karoly Palatka, Károly Palatka, Palatka Karoly

155

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University of Debrecen Semmelweis University University of Szeged University of Pecs University of Miskolc

About

Károly Palatka is an author at University of Debrecen specializing in medicine, gastroenterology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	391
2	Public Health	2	2	49
3	Health Sciences	1	1	31
4	Social Sciences	1	1	26
5	Diabetes	1	1	56

Károly Palatka

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort K Gecse, Barbara D. Lovász, Klaudia Farkas, Journal of Crohn s and Colitis	2015	182
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease László Kiss, Tamás Szamosi, Tamás Molnár, Alimentary Pharmacology & Therapeutics	2011	159
New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort Mária Papp, I Altorjay, Nir Dotan, The American Journal of Gastroenterology	2008	146
Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets Bertalan Meskó, Szilard Poliskal, Andrea Szegedi, BMC Medical Genomics	2010	117
Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy Tamás Molnár, Péter L. Lakatos, Klaudia Farkas, Alimentary Pharmacology & Therapeutics	2012	85
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis Klaudia Farkas, Mariann Rutka, Petra A. Golovics, Journal of Crohn s and Colitis	2016	81
Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohnʼs disease Péter L. Lakatos, Lajos S. Kiss, Károly Palatka, Inflammatory Bowel Diseases	2010	81
Seroreactivity to microbial components in Crohnʼs disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients Mária Papp, I Altorjay, Gary L. Norman, Inflammatory Bowel Diseases	2007	80
Pancreatic Autoantibodies Are Associated with Reactivity to Microbial Antibodies, Penetrating Disease Behavior, Perianal Disease, and Extraintestinal Manifestations, But Not with NOD2/CARD15 or TLR4 Genotype in a Hungarian IBD Cohort Péter L. Lakatos, I Altorjay, Tamás Szamosi, Inflammatory Bowel Diseases	2008	65
Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease Károly Palatka, Zoltán Serfözö, Zoltán Veréb, Scandinavian Journal of Gastroenterology	2005	60

Page 1